Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) will host a live webcast on March 2, 2026 at 4:30 p.m. ET to discuss preliminary, unaudited fourth quarter and full year 2025 financial results and provide a business update.
According to the company, the webcast link is available at the events page and a replay will be accessible for approximately 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – BLTE
In the Feb 23 session, BLTE gained 4.59%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Q3 2025 earnings | Positive | +3.7% | Q3 2025 results, DRAGON completion, financings and strong cash position. |
| Aug 11 | Q2 2025 earnings | Positive | -0.5% | Q2 2025 results, Breakthrough Therapy status and PHOENIX enrollment progress. |
| May 13 | Q1 2025 earnings | Positive | +1.2% | Q1 2025 results, DRAGON DSMB support and PHOENIX enrollment update. |
| Mar 17 | FY 2024 earnings | Positive | +0.5% | FY 2024 results, cash/investments detail and Tinlarebant trial progress. |
| Nov 12 | Q3 2024 earnings | Positive | +3.2% | Q3 2024 results, DRAGON II dosing, PHOENIX enrollment and cash update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past earnings/updates typically saw modest positive reactions around low-single-digit percentages, with only one mildly negative move.
Over the past year, Belite Bio’s earnings and corporate updates have paired financial reporting with steady clinical and regulatory progress. Events on Nov 10, 2025, Aug 11, 2025, and May 13, 2025 highlighted DRAGON and PHOENIX trial milestones, expanded cash balances, and additional financings. Price reactions around these earnings dates clustered near low-single-digit moves. Today’s planned webcast for preliminary Q4 and full-year 2025 results fits this pattern of using earnings dates as key clinical and funding update points.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025.
Webcast Information
Date: Monday, March 2, 2026
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/547616305
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook,or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Sophie Hunt
belite@argotpartners.com
